Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy

Basit Öğe Kaydı
dc.authorid0000-0003-2538-8569
dc.contributor.authorKaracin, Cengiz
dc.contributor.authorÖksüzoğlu, Berna
dc.contributor.authorDemirci, Ayşe
dc.contributor.authorKeskinkılıç, Merve
dc.contributor.authorBaytemür, Naziyet Köse
dc.contributor.authorYılmaz, Funda
dc.contributor.authorSelvi, Oğuzhan
dc.contributor.authorErdem, Dilek
dc.contributor.authorAvşar, Esin
dc.contributor.authorPaksoy, Nail
dc.contributor.authorDemir, Necla
dc.contributor.authorGöksu, Sema Sezgin
dc.contributor.authorTürker, Sema
dc.contributor.authorBayram, Ertuğrul
dc.contributor.authorÇelebi, Abdüssamet
dc.contributor.authorYılmaz, Hatice
dc.contributor.authorKuzu, Ömer Faruk
dc.contributor.authorKahraman, Seda
dc.contributor.authorGökmen, İvo
dc.contributor.authorSakin, Abdullah
dc.date.accessioned2023-02-24T07:21:14Z
dc.date.available2023-02-24T07:21:14Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractBackground: There is no standard treatment recommended at category 1 level in international guidelines for subsequent therapy after cyclin-dependent kinase 4/6 inhibitor (CDK4/6) based therapy. We aimed to evaluate which subsequent treatment oncologists prefer in patients with disease progression under CDKi. In addition, we aimed to show the effectiveness of systemic treatments after CDKi and whether there is a survival difference between hormonal treatments (monotherapy vs. mTOR-based). Methods: A total of 609 patients from 53 centers were included in the study. Progression-free-survivals (PFS) of subsequent treatments (chemotherapy (CT, n:434) or endocrine therapy (ET, n:175)) after CDKi were calculated. Patients were evaluated in three groups as those who received CDKi in first-line (group A, n:202), second-line (group B, n: 153) and ? 3rd-line (group C, n: 254). PFS was compared according to the use of ET and CT. In addition, ET was compared as monotherapy versus everolimus-based combination therapy. Results: The median duration of CDKi in the ET arms of Group A, B, and C was 17.0, 11.0, and 8.5 months in respectively; it was 9.0, 7.0, and 5.0 months in the CT arm. Median PFS after CDKi was 9.5 (5.0–14.0) months in the ET arm of group A, and 5.3 (3.9–6.8) months in the CT arm (p = 0.073). It was 6.7 (5.8–7.7) months in the ET arm of group B, and 5.7 (4.6–6.7) months in the CT arm (p = 0.311). It was 5.3 (2.5–8.0) months in the ET arm of group C and 4.0 (3.5–4.6) months in the CT arm (p = 0.434). Patients who received ET after CDKi were compared as those who received everolimus-based combination therapy versus those who received monotherapy ET: the median PFS in group A, B, and C was 11.0 vs. 5.9 (p = 0.047), 6.7 vs. 5.0 (p = 0.164), 6.7 vs. 3.9 (p = 0.763) months. Conclusion: Physicians preferred CT rather than ET in patients with early progression under CDKi. It has been shown that subsequent ET after CDKi can be as effective as CT. It was also observed that better PFS could be achieved with the subsequent everolimus-based treatments after first-line CDKi compared to monotherapy ET.
dc.description.sponsorshipBreast Cancer Consortiumen_US
dc.identifier.citationKaracin, C., Öksüzoğlu, B., Demirci, A., Keskinkılıç, M., Baytemür, N. K., Yılmaz, F. ... Sakin, A. (2023). Efficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy. BMC Cancer, 23(1). https://doi.org/10.1186/s12885-023-10609-8
dc.identifier.doi10.1186/s12885-023-10609-8
dc.identifier.issn1471-2407
dc.identifier.issue1
dc.identifier.pmid36765293
dc.identifier.scopus2-s2.0-85147894207
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://doi.org/10.1186/s12885-023-10609-8
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10524
dc.identifier.volume23
dc.identifier.wos000980043700010en_US
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorSakin, Abdullah
dc.language.isoen
dc.publisherBioMed Central Ltd
dc.relation.ispartofBMC Canceren_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsAttribution 4.0 International*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/*
dc.subjectAdvanced Breast Cancer
dc.subjectCyclin-Dependent Kinase
dc.subjectRibociclib
dc.subjectPalbociclib
dc.subjectEverolimus
dc.subjectFulvestrant
dc.subjectEndocrine Treatment
dc.subjectHormonotherapy
dc.titleEfficacy of subsequent treatments in patients with hormone-positive advanced breast cancer who had disease progression under CDK 4/6 inhibitor therapy
dc.typeArticle

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Sakin-Abdullah-2023.pdf
Boyut:
1.57 MB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Makale Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu